Thierry Bogaert is a Belgian scientist and businessman. He founded the Belgian biotech company Devgen in 1997 and was its managing director and CEO from 1997 onwards, until he sold the Devgen to Syngenta in 2012 for 400m EUR. During this time he led the science and business strategy of the company and took Devgen public on Euronext in 2005. Building on genetics as its core scientific strength, He developed Devgen into a leading provider of new crop protection technologies to the Agro industry and an Asian seed company that fundamentally redesigned Hybrid Rice delivering a pipeline of high yielding products for Indian and South East Asian markets. Prior to its sale to Syngenta, Devgen seeds were produced on >8000 ha and sold in ~20,000 retail shops across India, Indonesia and Philippines.
Education
editHe graduated from the University of Ghent (Ghent, Belgium) and received an MSc degree form the University of Manitoba (Winnipeg, Manitoba, Canada). He obtained a PhD at the Laboratory of Molecular Biology, Medical Research Council, (Cambridge, United Kingdom).
Career
editAs an academic, he held faculty positions at the Laboratory of Molecular Biology of the Medical Research Council (MRC-LMB) in Cambridge and the Medical Faculty of the University of Ghent. His research interest was about Drosophila melanogaster integrins[1][2] and a Caenorhabditis elegans UNC gene (uncoordinated phenotype).[3]
In 1997, he founded DevGen and became its chief executive officer.
References
edit- ^ Bogaert T, Brown N, Wilcox M, The Drosophila PS2 antigen is an invertebrate integrin that, like the fibronectin receptor, becomes localized to muscle attachments, Cell. 1987 Dec 24;51(6):929–40
- ^ Leptin M, Bogaert T, Lehmann R, Wilcox M, The function of PS integrins during Drosophila embryogenesis, Cell. 1989 Feb 10;56(3):401–8
- ^ Stringham E, Pujol N, Vandekerckhove J, Bogaert T, unc-53 controls longitudinal migration in C. elegans, Development. 2002 Jul;129(14):3367–79